Alliance Pharma Acquires LGC's Drug Development Solutions Business | citybiz
Alliance Pharma has acquired Drug Development Solutions and attracted KKR as a backer
Ampersand Portfolio Company U.S. Alliance Pharma Acquires U.K.-based LGC's Drug Development Solutions (DDS) Business | Ampersand Capital
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business (“DDS”) and welcomes KKR as joint shareholder | Ampersand Capital
À propos de nous - Nexelis, a Q² Solutions Company
Branden Berns on LinkedIn: It's official. The new year has been an excellent occasion to reflect on… | 114 comments
Ampersand Capital Partners on LinkedIn: EPC Autumn 2022
Ampersand adds another CMDO to portfolio - BioProcess InsiderBioProcess International
Ampersand Capital Partners på LinkedIn: U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into…
In the News
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC